At what enterprise value was APRIOMED acquired in 2023?

During the acquisition of APRIOMED by HALMA in 2023, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 100M - 350M SEK. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of APRIOMED when it was acquired by HALMA?

The exact EV/EBITDA multiple for APRIOMED is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was APRIOMED acquired by HALMA?

APRIOMED was acquired by HALMA in 2023.

What was the revenue of APRIOMED at the time of the deal?

The revenue of APRIOMED at the time of the deal is estimated to be in the range of 25M - 50M SEK. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the APRIOMED acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the APRIOMED deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.halma.com/news/press-releases/2023/halma-expands-in-environmental-and-analysis-and-healthcare-sectors-with-acquisitions

← DATABASE

Home Database Healthcare & PharmaAPRIOMED

04/2023

APRIOMED acquired by HALMA

SWEDEN Life Sciences / Medical Devices EV 100M - 350M SEK

Context

The successful acquisition of AprioMed by IZI Medical Products represents a tactical expansion of Halma’s healthcare portfolio in the interventional radiology segment. This transaction marks the integration of AprioMed’s highly specialized bone biopsy technology, effectively widening the technical operational depth available to IZI Medical’s global clinical customer base. The strategic rationale centers on the industrial synergy between AprioMed’s minimally invasive instruments and IZI Medical’s established oncology and radiology portfolio, allowing for a more verticalized patient diagnosis solution. By incorporating AprioMed, IZI Medical reinforces its ability to address the increasing demand for cancer diagnosis tools driven by an aging global population. The partnership is designed to leverage IZI Medical’s existing global distribution channels and direct international presence to drive the scaling of AprioMed’s proprietary hardware. This integration facilitates a more robust clinical platform, providing the strategic depth required to navigate the complex evolution of the global healthcare landscape. The move solidifies the group’s standing as a primary enabler of diagnostic precision and manufacturing excellence.

APRIOMED, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

AprioMed operates as a premier engineering and manufacturing entity dedicated to the production of high-precision medical devices for bone biopsy procedures. The organization’s business model centers on a sophisticated proprietary framework for needles and specialized instrumentation utilized within interventional radiology and oncology. A key pillar of its value proposition lies in its technical operational depth in minimally invasive technology, providing physicians with reliable, high-performance tools for complex clinical diagnostics. Strategically, AprioMed focuses on the integration of direct clinical feedback into its design process to ensure procedural safety and extreme accuracy in tissue sampling. By occupying this specialized niche in the diagnostic supply chain, the entity facilitates superior outcomes for global healthcare providers managing cancer and bone-related conditions. The organization prioritizes technical reliability and manufacturing excellence to maintain its standing as an essential partner in the micro-interventional ecosystem.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (SEK)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
07/2023	LAUXERA	ORGANOX	UNITED KINGDOM	Life Sciences	Lauxera Capital Partners has successfully led a £25 million growth investment into OrganOx, marking a pivotal minority platform entry into the high-barrier medical technology sector. Based in Oxford, England, the commercial-stage enterprise represents a strategic addition to the investor's specialized healthcare portfolio
06/2023	NOVO NORDISK	BIOCORP	FRANCE	Life Sciences	The acquisition of Biocorp by Novo Nordisk, achieved through the purchase of Bio Jag's 45.3% stake and a subsequent mandatory public tender offer, marks a significant shift in strategy, transitioning from a collaborative research and development model to a proprietary technology platform
04/2023	SARTORIUS	POLYPLUS	France	Life Sciences	Sartorius Stedim Biotech has reached a definitive agreement to acquire one hundred percent of the share capital of Polyplus from private equity sponsors ArchiMed and Warburg Pincus. This landmark transaction is structured as a full buyout, effectively transferring ownership from financial sponsors to a strategic corporate acquirer
02/2023	ARDIAN	THERADIAL	FRANCE	Life Sciences	Ardian has acquired a stake in Théradial, a specialized player in the French dialysis sector, with a consolidated presence in medical product distribution, pharmaceuticals, and healthcare software. This transaction is part of a strategic partnership with UI Investissement, which had previously invested in the company in 2017
10/2022	IK PARTNERS	UNITHER	FRANCE	Life Sciences	Unither Pharmaceuticals, a global leader in sterile single-unit dosage manufacturing, has undergone a capital reorganization led by its management team and a consortium of prominent investors. GIC and IK Partners have entered as new equity partners, while Keensight Capital and Parquest are reinvesting to reinforce their existing positions
10/2022	STANLEY CAPITAL PARTNERS	LABORATOIRE X.O	FRANCE	Life Sciences	Stanley Capital Partners acquired a majority stake in Laboratoire X.O following the liquidation of its former owner, Novalpina Capital. The deal resolved a year-long legal dispute between management and transitional managers (BRG)
08/2022	CATALENT	METRICS CONTRACT SERVICES	UNITED STATES	Life Sciences	Catalent has executed a definitive binding agreement to acquire Metrics Contract Services, a specialized CDMO subsidiary, from Australia-based Mayne Pharma Group. Concurrently with the main transaction, the parties established a five-year commercial supply agreement alongside a transition service agreement (TSA), ensuring a seamless operational integration and absolute supply continuity for the divesting parent’s retained product portfolio
07/2022	TPG	DOC GENERICI	ITALY	Life Sciences	TPG Capital has signed a binding agreement to acquire a majority stake in DOC Generici from ICG and Mérieux Equity Partners. The strategic rationale for the transaction is driven by the continued expansion of the Italian generic drug market and DOC Generici's position as a reference brand for patients and healthcare providers
07/2022	MERIEUX EQUITY PARTNERS	THERAVIA	FRANCE	Life Sciences	Healthcare-focused investment firm Mérieux Equity Partners has completed the strategic merger of two of its existing portfolio companies, Addmedica and Laboratoires CTRS, creating a new consolidated entity named Theravia Pharma
06/2022	UI INVESTISSEMENT / GENEO	NEFTYS PHARMA	FRANCE	Life Sciences	A consortium of prominent financial sponsors, led by UI Investissement and supported by GENEO Capital Entrepreneur alongside historical partner Crédit Agricole Centre France, has successfully executed a growth equity investment in Neftys Pharma

REFERENCES

Valuation range: EV 100M - 350M SEK

Revenue range: 25M - 50M SEK

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of APRIOMED by HALMA are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: halma